节点文献

恶性浆膜腔积液的ras基因突变和P21~(ras)蛋白表达状况及其诊断价值

ras Gene Mutations and P21~(ras) Expression in Malignant Serous Cavity Effusions and Their Diagnostic Values

【作者】 宋荣峰

【导师】 张焜和;

【作者基本信息】 江西医学院 , 内科学消化, 2003, 硕士

【摘要】 Objective Serosa metastatic carcinomas usually cause malignant serous cavity effusions. The differentiation between malignant and benign effusions is sometimes difficult but very important in clinical practice. Laboratory tests are essential to the differentiation, but current available tests can not solve the problem satisfactorily. Ras gene is an important proto-oncogene, and its mutations are frequently found in many malignant tumors. Detecting ras gene mutations and expression in effusions is probably useful in differentiating malignant effusions from benign ones. In the present study, point mutations of codon 12 of K-ras and H-ras gene in the effusion supernatants were detected by polymerase chain reaction with restriction fragment length polymorphism (PCR-RFLP) and P21ras expressions in the effusion exfoliative cells were detected by immunocytochemistry, and their values in diagnosis of malignant effusions were evaluated.Methods Fresh specimens of serous cavity effusions were obtained. Exfoliative cells and supernatants were collected after centrifugation, respectively. Two cell smears were prepared for Papanicolaou staining and cytological diagnosis, by which the specimens were divided into benign and malignant effusions. Genome DNA in the supernatants was conventionally extracted by proteinase K digestion followed by phenol/chloroform extraction. The DNA fragments containing codon 12 of K-ras and H-ras gene were amplified by PCR, respectively, and were cleaved by restriction endonuclease Mva I or Msp I, respectively. Digestive products were purified and identified by<WP=6>means of polyacrylamide gel electrophoresis and silver staining. On the other hand, some of exfoliative cells were processed with a "standardized" procedure: removing red cells (when existing), fixed in 1% paraformaldehyde, resuspended in a solution of 1% BSA-PBS, adjusting the cell concentration to 2×106 cells per milliliter, and finally cell smears were prepared for immunocytochemistry. The primary antibody was monoclonal mouse anti-human P21ras, the second antibody was the biotinylated goat anti-mouse IgG. Streptavidin labeled with horseradish peroxidase was as the enzyme system. The color was developed with DAB. Results were observed under a light microscope. Results A total of 108 specimens of serous cavity effusions were collected, including 53 cases of malignant effusions and 55 cases of benign effusions. PCR amplification of codon 12 of K-ras and H-ras genes was successful in 101 supernatants of the specimens (93.5%). In 52 malignant specimens, the codon 12 mutation rates of K-ras and H-ras gene were 55.8% and 30.8%, respectively. In 49 benign specimens, the mutation rates were 10.2% and 4.1%. The differences of the mutation rates of K-ras or H-ras were significant between benign and malignant effusions (P<0.001). The specificities (Sp) of K-ras and H-ras gene mutation for the diagnosis of malignant effusions were 89.8% and 95.9%, the positive predictive values (PV+) were 85.3% and 88.9%, the negative predictive values (PV-) were 65.8% and 56.6%, and the diagnostic accordance rates (DAR) were 72.3% and 62.4%.For the immunocytochemical staining of P21ras, tumor exfoliative cells in 39 of 53 cases (73.6%) of malignant effusions were positive, and most of them expressed strongly. The positive results were observed in 12 of 55 cases (21.8%) of benign effusions, and most of them expressed weakly. The differences of positive rates and expression intensity of P21ras were significant between malignant and benign effusions (P<0.001). Sp of P21ras immunocytochemistry in diagnosis of malignant effusions was 78.2%, PV+ 76.5%, PV 75.4% and DAR 75.9%.Combination analysis of ras gene mutation and P21ras immunocytochemical<WP=7>staining in a parallel and series way, sensitivities for the diagnosis of malignant effusions were 88.7% and 49.1%, Sp 69.1% and 96.4%, PV+ 73.4% and 92.9%, PV- 86.4% and 63.9%, DAR 78.7% and 73.2%. Parallel combination analysis enhances the sensitivity and series combination analysis enhances the s

【Abstract】 Objective Serosa metastatic carcinomas usually cause malignant serous cavity effusions. The differentiation between malignant and benign effusions is sometimes difficult but very important in clinical practice. Laboratory tests are essential to the differentiation, but current available tests can not solve the problem satisfactorily. Ras gene is an important proto-oncogene, and its mutations are frequently found in many malignant tumors. Detecting ras gene mutations and expression in effusions is probably useful in differentiating malignant effusions from benign ones. In the present study, point mutations of codon 12 of K-ras and H-ras gene in the effusion supernatants were detected by polymerase chain reaction with restriction fragment length polymorphism (PCR-RFLP) and P21ras expressions in the effusion exfoliative cells were detected by immunocytochemistry, and their values in diagnosis of malignant effusions were evaluated.Methods Fresh specimens of serous cavity effusions were obtained. Exfoliative cells and supernatants were collected after centrifugation, respectively. Two cell smears were prepared for Papanicolaou staining and cytological diagnosis, by which the specimens were divided into benign and malignant effusions. Genome DNA in the supernatants was conventionally extracted by proteinase K digestion followed by phenol/chloroform extraction. The DNA fragments containing codon 12 of K-ras and H-ras gene were amplified by PCR, respectively, and were cleaved by restriction endonuclease Mva I or Msp I, respectively. Digestive products were purified and identified by<WP=6>means of polyacrylamide gel electrophoresis and silver staining. On the other hand, some of exfoliative cells were processed with a "standardized" procedure: removing red cells (when existing), fixed in 1% paraformaldehyde, resuspended in a solution of 1% BSA-PBS, adjusting the cell concentration to 2×106 cells per milliliter, and finally cell smears were prepared for immunocytochemistry. The primary antibody was monoclonal mouse anti-human P21ras, the second antibody was the biotinylated goat anti-mouse IgG. Streptavidin labeled with horseradish peroxidase was as the enzyme system. The color was developed with DAB. Results were observed under a light microscope. Results A total of 108 specimens of serous cavity effusions were collected, including 53 cases of malignant effusions and 55 cases of benign effusions. PCR amplification of codon 12 of K-ras and H-ras genes was successful in 101 supernatants of the specimens (93.5%). In 52 malignant specimens, the codon 12 mutation rates of K-ras and H-ras gene were 55.8% and 30.8%, respectively. In 49 benign specimens, the mutation rates were 10.2% and 4.1%. The differences of the mutation rates of K-ras or H-ras were significant between benign and malignant effusions (P<0.001). The specificities (Sp) of K-ras and H-ras gene mutation for the diagnosis of malignant effusions were 89.8% and 95.9%, the positive predictive values (PV+) were 85.3% and 88.9%, the negative predictive values (PV-) were 65.8% and 56.6%, and the diagnostic accordance rates (DAR) were 72.3% and 62.4%.For the immunocytochemical staining of P21ras, tumor exfoliative cells in 39 of 53 cases (73.6%) of malignant effusions were positive, and most of them expressed strongly. The positive results were observed in 12 of 55 cases (21.8%) of benign effusions, and most of them expressed weakly. The differences of positive rates and expression intensity of P21ras were significant between malignant and benign effusions (P<0.001). Sp of P21ras immunocytochemistry in diagnosis of malignant effusions was 78.2%, PV+ 76.5%, PV 75.4% and DAR 75.9%.Combination analysis of ras gene mutation and P21ras immunocytochemical<WP=7>staining in a parallel and series way, sensitivities for the diagnosis of malignant effusions were 88.7% and 49.1%, Sp 69.1% and 96.4%, PV+ 73.4% and 92.9%, PV- 86.4% and 63.9%, DAR 78.7% and 73.2%. Parallel combination analysis enhances the sensitivity and series combination analysis enhances the s

【关键词】 目的 恶性肿瘤的浆膜转移常引起恶性浆膜腔积液,后者有时与良性浆膜腔积液难以鉴别,但正确鉴别两者具有重要的临床意义。良恶性浆膜腔积液的鉴别主要依赖实验室检查,但现有的实验诊断技术有时不能满意地解决这一问题。ras基因是重要的原癌基因,其突变常见于多种恶性肿瘤,检测ras基因突变及其蛋白表达情况可能对鉴别良恶性积液具有重要的临床价值。本研究采用PCR-RFLP技术检测浆膜腔积液上清液中K-ras和H-ras基因12位点的突变状况,采用免疫细胞化学染色技术检测浆膜腔积液脱落细胞P21ras蛋白表达状况,探讨它们对恶性浆膜腔积液诊断中的价值。方法 收集新鲜浆膜腔积液标本,常规离心后收集上清和脱落细胞。取部分脱落细胞涂片,作巴氏染色进行常规细胞学诊断,将积液分为良性与恶性两组。以上清为材料,采用常规蛋白酶K消化、酚/氯仿抽提法提取基因组DNA,然后采用PCR技术分别扩增包含K-ras和H-ras基因12位点的DNA片段,并对扩增产物分别用限制性内切酶Mva I和Msp Ι进行酶切消化,对消化产物纯化后进行聚丙烯酰胺凝胶电泳及硝酸银染色显示结果。同时,对脱落细胞作“标准化”处理,包括去除红细胞(存在时)、1%多聚甲醛-PBS固定、用1%BSA-PBS制备细胞悬液、调整细胞浓度为2×106/ml,然后制备细胞涂片进行免疫细胞染色,一抗为鼠抗人ras单克隆抗体,二抗为生物素标记的羊抗鼠IgG,辣根酶标记链霉卵白素为酶系统,DAB显色,高倍光镜下判读结果。结果 108例浆膜腔积液标本中,恶性积液53例,良性积液55例。101例K-ras和H-ras基因12位点扩增获得成功(93.5%),其中52例恶性积液中K-ras和H-ras基因12位点突变率分别为55.8%和30.8%,49例良性积液中突变率分别为10.2%和4.1%,两种不同性质积液上清的K-ras和H-ras基<WP=4>因的突变率差异均有显著性统计学意义(P<0.001)。K-ras和H-ras基因12位点突变诊断恶性积液的特异性为89.8%和95.9%,阳性预测值为85.3%和88.9%,阴性预测值65.8%和56.6%,诊断符合率72.3%和62.4%。53例恶性积液中有39例肿瘤细胞P21ras蛋白免疫细胞化学染色阳性(73.6%),且多为强阳性或阳性55例良性积液中有12例可见P21ras蛋白免疫细胞化学染色阳性(21.8 %),且皆为阳性或弱阳性。两组间染色的阳性率及阳性强度的差异均有显著性统计学意义(P<0.001)。P21ras蛋白免疫细胞化学染色诊断恶性积液的特异性为78.2%,阳性预测值76.5%,阴性预测值75.4%,诊断符合率达75.9%。将ras基因突变和P21ras蛋白免疫细胞化学染色进行并联式和串联式联合分析,对诊断恶性积液的敏感性为88.7%和49.1%,特异性为69.1%和96.4%,阳性预测值为73.4%和92.9%,阴性预测值为86.4%和63.9%,诊断符合率为78.7%和73.2%。并联式联合分析可提高诊断敏感性,串联式分析则提高诊断的可靠性。结论1.恶性浆膜腔积液上清中K-ras基因12位点突变频率较高,对诊断恶性浆膜腔积液有一定的临床价值。2.恶性浆膜腔积液上清中H-ras基因12位点突变频率较低,对诊断恶性浆膜腔积液的临床价值较小。3.浆膜腔积液中脱落肿瘤细胞P21ras蛋白免疫细胞化学染色多为阳性,良性细胞多为阴性,对恶性体腔积液的诊断有较大的价值。4.ras基因突变和P21ras蛋白表达联合检测,有助于提高诊断恶性积液的敏感性或特异性,提高恶性积液的检出率或诊断可靠性。5.浆膜腔积液标本离心后取微量上清,采用常规酚/氯仿法即可提取出基因组DNA,能成功用于PCR-RFLP分析。
【Key words】 K-ras geneH-ras geneGene mutationP21ras proteinSerous cavity effusionPCR-RFLPImmunocytochemistry
  • 【网络出版投稿人】 江西医学院
  • 【网络出版年期】2004年 03期
  • 【分类号】R730.4
  • 【下载频次】89
节点文献中: 

本文链接的文献网络图示:

本文的引文网络